Vai alla homepage
4.6/5
TrustPilot

I migliori medici di Terapia ormonale a Istanbul - TOP-8 medici

Confronta i migliori medici di Terapia ormonale e i prezzi in Turchia. Trova qui la tua scelta ideale.

Richiedi preventivi da 3 migliori specialisti di Terapia ormonale in Turchia

Selezioneremo i migliori medici in base alle tue esigenze e al tuo budget.

Medici top

8

Turchia

Recensioni

14000+

Da pazienti reali

Scegli il paese con i migliori prezzi per i servizi medici

Confronta i prezzi di Terapia ormonale nei principali paesi

Tocca un paese per vedere i migliori medici e i prezzi

Turkey
Ukraine
Mexico
Thailand
Poland
South Korea
$400 - $1,000
$1,200 - $2,500
$1,200 - $2,100
$1,800 - $3,200
$1,800 - $3,200
$2,000 - $5,200
$0
$1,000
$2,000
$3,000
$4,000
$5,000
$6,000

Quanto pagano davvero i pazienti Bookimed per Terapia ormonale in Turchia

Gamma più richiesta

$200

$300

$400

$600

$800

$100 – $300

La maggior parte dei pazienti paga in questa fascia

Il costo esatto dipende dal medico scelto, dalla tecnica, dalle aree trattate e dalle tue esigenze individuali.

Ottieni un preventivo preciso per il tuo caso.

Ricevi piani di trattamento personalizzati gratuiti e scegli l'opzione migliore. Nessun impegno · Nessun costo per i nostri servizi

Mostra prima:

55 persone hanno richiesto un preventivo lo scorso mese

Eda Tanrikulu

  • 5 Eccellente 2 recensioni
  • 21 anni di esperienza
  • Località: Turchia, Istanbul
  • Il medico è un oncologo molto rispettato presso l'Anadolu Medical Center, specializzato in oncologia medica e chemioterapia. Dopo aver conseguito una laurea in medicina presso l'Università di Ankara nel 2005, il medico ha completato la formazione specialistica in medicina interna presso l'Università di Istanbul e si è ulteriormente specializzato in oncologia medica presso l'Università di Marmara entro il 2017. Il medico ha guidato l'unità di oncologia medica presso l'Ospedale di Formazione e Ricerca Haydarpaşa Numune e ha partecipato a numerosi studi clinici internazionali. Il medico si concentra su un'ampia gamma di tumori, inclusi quelli al seno, urologici, polmonari e gastrointestinali, tra gli altri.<\/p>

    Il medico è membro di diverse società oncologiche prestigiose, tra cui la Società Turca di Oncologia Medica, la Società Europea di Oncologia Medica e la Società Americana di Oncologia Medica. Il medico ha partecipato a programmi di formazione avanzata a livello globale, inclusi programmi presso l'Università di Oxford e ESMO.<\/p>

  • Mostra di più
Visita dal medico
Prezzo su richiesta

32 persone hanno richiesto un preventivo lo scorso mese

Mustafa Solak

  • 5 Eccellente 1 recensioni
  • 20 anni di esperienza
  • Località: Turchia, Istanbul
  • Fellowship presso l'Istituto Tumori dell'Università di Hacettepe – Il Dr. Solak è specializzato nella terapia ormonale per diversi tipi di cancro.

    • Si occupa di tumori al seno, testicolo, ovaio e polmone
    • Residency presso l'Istanbul Sisli Etfal Training Hospital
    • Formazione presso The University of Texas MD Anderson Cancer Center
    • Esperto in tumori gastrointestinali e della testa-collo
  • Mostra di più
Visita dal medico
Prezzo su richiesta

Abdullah Sakin

  • 19 anni di esperienza
  • Località: Turchia, Istanbul
  •  

    Experience

    2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

     

    2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

     

    2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

     

    2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

     

    2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

     

    2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

     

    2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

     

    2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

     

    2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

     

    2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

     

    2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

     

    2008 - 2012 Haseki Training and Research Hospital

     

    2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

     

     

    Education

    2018

    İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

    2018

    İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

    2012

    İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

    2012

    İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

    2007

    Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

     

  • Mostra di più
Visita dal medico
Prezzo su richiesta

Yesim Yildirim

  • 5 Eccellente 10 recensioni
  • 22 anni di esperienza
  • accreditamenti:
  • Località: Turchia, Istanbul
  • La professoressa Yesim Yildirim è specializzata in immunoterapia del cancro e terapie mirate, con oltre 80 pubblicazioni in oncologia medica.

    • Membro della Società Europea di Oncologia Medica (ESMO)
    • Esperta in tumori della mammella, gastrointestinali e polmonari
    • Professoressa presso l'Università di Halic, Istanbul
    • Ha completato la formazione avanzata presso la Clinica di Melanoma e Cancro del Rene a Londra
  • Mostra di più
Visita dal medico
Prezzo su richiesta

Dr. Sezer Saglam

  • 5 Eccellente 1 recensioni
  • 29 anni di esperienza
  • accreditamenti:
  • Località: Turchia, Istanbul
  • Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

    Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

  • Mostra di più
Visita dal medico
Prezzo su richiesta

Nail Paksoy

  • 15 anni di esperienza
  • accreditamenti:
  • Località: Turchia, Istanbul

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Mostra di più
Visita dal medico
Prezzo su richiesta

Irfan Cicin

  • 29 anni di esperienza
  • Località: Turchia, Istanbul
  • Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

    Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

    Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

  • Mostra di più
Visita dal medico
Prezzo su richiesta

Cagdas Erdogan

  • 12 anni di esperienza
  • Località: Turchia, Istanbul
  • Dr. Cagdas Erdogan is a gastroenterologist at Ankara Etlik City Hospital. He trained in Internal Medicine and Gastroenterology. He earned his MD from Dokuz Eylul University. He completed his Internal Medicine residency from 2014 to 2019. He then completed a Gastroenterology fellowship at Ankara City Hospital from 2019 to 2022. His clinical focus includes advanced endoscopy (ERCP, EUS, EMR, ESD, POEM, EGD, colonoscopy, double-balloon enteroscopy), inflammatory bowel disease, and hepatology.

    He has about 40 publications. His work appears in The Turkish Journal of Gastroenterology, Scientific Reports, Endoscopy, and Digestive Diseases and Sciences. Notable studies address vedolizumab in IBD and prophylaxis for post-ERCP pancreatitis. He also reported a 13-year Crohn’s cohort comparing infliximab and adalimumab. Additional work covers outcomes with an adalimumab biosimilar and innovative endoscopic therapies (MCA via double-balloon enteroscopy, holmium laser for Bouveret syndrome, POEM for Zenker’s diverticulum, and ESD for esophageal papillomatosis).

  • Mostra di più
Visita dal medico
Prezzo su richiesta

Scegliere una clinica all'estero può essere stressante. Da Bookimed, con oltre 800.000 pazienti aiutati, comprendiamo le tue preoccupazioni. Sappiamo come trovare medici affidabili, le migliori opzioni per rapporto qualità-prezzo e soluzioni anche per casi complessi. Siamo qui per guidarti in ogni fase del tuo percorso sanitario.

Yan Matsiivskiy

Capo del team dei coordinatori medici

Oltre 4300+ viaggi assistiti di pazienti

3 anni su Bookimed

278 pazienti da Turkey hanno trovato il loro medico tramite noi questo mese

Come troverai il medico perfetto per te

1

Quiz da 2 minuti

Dicci il tuo obiettivo, budget e tempistiche

2

Abbinamento umano + IA

Il nostro algoritmo trova le corrispondenze, il coordinatore verifica l'idoneità

3

Le tue opzioni pronte

Confronta prezzi, pacchetti, date. Chatta con il tuo coordinatore

Tante opzioni e non sai cosa scegliere?

Il tuo personale Il coordinatore Bookimed ti aiuta a trovare il chirurgo perfetto per le tue esigenze

  • Ti supporta 24/7 in ogni fase
  • Ti aiuta a trovare il medico più adatto e gestisce tutte le comunicazioni con le cliniche
  • Coordina viaggio, alloggio e trasferimenti

Guida il tuo percorso di cura

Coordinatori personali medici qualificati

Peguy Beaugris
Tetyana Hyrych
Zekra Eldeeb
Victoria Olayinka
Iryna Sydorchuk
Tetiana Ihnatiuk

Come scegliere il medico e la clinica giusti: consigli degli esperti

Quando scegli un medico o una clinica, tieni presente questi punti chiave:
Controlla le credenziali
Verifica le certificazioni di enti come ISAPS, JCI o degli ordini medici pertinenti.
Verifica i tassi di successo
Scegli medici con grande esperienza e comprovata competenza nel trattamento specifico.
Leggi le recensioni dei pazienti
Recensioni reali dei pazienti Bookimed per conoscere la loro esperienza.
Assicura una comunicazione efficace
Scegli cliniche che offrono servizio di traduzione per facilitare il trattamento.
Chiedi informazioni sui servizi
Conferma se il prezzo include servizi come alloggio, trasferimenti locali e assistenza post-trattamento per evitare costi nascosti.

Bookimed Insights: Principali specialisti in Terapia ormonale in Turchia (2026)

Bookimed ha coordinato 30 richieste per Terapia ormonale in Turchia, collaborando con 8 specialisti di alto livello. I medici in questa tabella sono selezionati in base alle loro credenziali internazionali, esperienza clinica e risultati dei pazienti. La classifica del 2026 è composta da dati verificati su casi reali e dai programmi attuali delle nostre cliniche partner.
ClassificaMedicoesperienzaBuona scelta perCosa li distingueClinica e posizioneConsulto
#120 anni di esperienzaTerapia ormonale per il cancroSpecializzato in oncologia con formazione presso il MD Anderson. Specializzato in terapie ormonali per i tumori al seno, ai testicoli, alle ovaie e ai polmoni.
Turchia
da $100
#222 anni di esperienzaTumori al seno e gastrointestinaliSpecializzato in immunoterapia del cancro e terapie mirate. Membro dell'ESMO con formazione avanzata a Londra. Professore presso l'Università di Halic.
Turchia
da $215

FAQ

Queste domande frequenti provengono da pazienti reali che cercano assistenza medica tramite Bookimed. Le risposte sono fornite da coordinatori medici esperti e rappresentanti affidabili delle cliniche.

Which Turkish doctors are internationally certified for hormone therapy?

Turkish hormone therapy specialists hold certifications from the European Society for Medical Oncology and ASCO. Many doctors maintain ECFMG accreditation. These experts work in JCI-accredited hospitals like Memorial Sisli. They follow international protocols for menopause and oncology care.

  • Dr. Esra Ozbasli: She trained at New York University and holds USA ECFMG accreditation.
  • Prof. Dr. Yesim Yildirim: This ESMO-certified oncologist works at the Anadolu Medical Center.
  • Dr. Serkan Keskin: He leads oncology at Memorial Sisli and holds ASCO memberships.
  • Prof. Dr. Irfan Cicin: He belongs to the European Neuroendocrine Tumor Society at Istinye University.

Bookimed Expert Insight: Turkish specialists often combine endocrine expertise with international research backgrounds. Dr. Esra Ozbasli at Acibadem Altunizade has 20+ years of experience. Prof. Dr. Yesim Yildirim practices at a Johns Hopkins affiliate. This connection provides access to global diagnostic standards.

Patient Consensus: Patients note the detailed explanations provided during their initial consultations. Many felt relieved by the clear communication from coordinators and doctors. They appreciate the organized travel logistics provided for their treatment stay.

How many years of hormone-therapy experience do top doctors in Turkey usually have?

Top hormone therapy specialists in Turkey typically possess 20+ years of clinical practice. Most leading experts hold board certifications in endocrinology, oncology, or gynecology. These doctors often train at prestigious institutions across Europe and the United States before joining JCI-accredited hospitals.

  • Extensive clinical practice: Senior endocrinologists frequently have over 25 years of medical experience.
  • Specialized oncological training: Medical oncologists often bring 20+ years of experience in hormonal protocols.
  • Reproductive health expertise: Gynecologists specializing in BHRT typically possess over 20 years of practice.
  • International fellowship training: Many top doctors completed advanced specialty fellowships in global medical hubs.

Bookimed Expert Insight: Data shows that Turkey’s leading endocrinologists, like Dr. Aydogan Aydogdu with 25+ years of experience, often combine clinical work with academic research. This unique pattern means patients receive care from doctors who simultaneously develop new treatment protocols. Bookimed observes that these academic-level specialists are concentrated in Istanbul and Ankara hospitals.

Patient Consensus: Patients often mention how comfortable they feel with such experienced doctors. They noticed that senior specialists explain complex hormonal shifts in very simple terms. Many felt relieved that their doctor had treated similar cases for over two decades.

What qualifications should I look for when choosing a hormone-therapy doctor in Turkey?

Qualified hormone therapy doctors in Turkey hold specialization in endocrinology or reproductive medicine. Look for surgeons with Turkish Board certification. They should work in hospitals with JCI accreditation. Many lead doctors undergo international fellowship training. This ensures they follow global safety protocols for hormonal treatments.

  • Board certification: Doctors must be registered with the Turkish Medical Association (TTB).
  • Specialized training: Seek experts in Endocrinology and Metabolic Diseases for complex cases.
  • Accredited facilities: Top physicians operate in hospitals with JCI or TEMOS certifications.
  • Clinical experience: Choose specialists with over 15 years in metabolic or reproductive care.

Bookimed Expert Insight: Data shows a trend of dual-certified specialists in Istanbul. Many top-rated doctors hold certifications in both gynecology and endocrinology. Dr. Erkan Akan at Memorial Bahçelievler Hospital is a prime example. This combination is vital for managing menopause or reproductive health effectively. It provides more comprehensive care than a single-specialty approach.

Patient Consensus: Patients often mention how clearly doctors explain lab results. They felt relieved when doctors adjusted doses based on specific symptoms. Many found the coordination of translators and airport pickups very helpful.

How much do respected hormone-therapy doctors charge for an initial consultation in Turkey?

Respected hormone therapy doctors in Turkey charge between $115 and $125 for an initial consultation. These specialists often hold Turkish Board of Endocrinology and Metabolism certifications. Many have over 20+ years of experience. Costs remain lower than US averages for expert hormonal evaluations.

  • Specialist fees: Initial consultations with endocrinologists typically range from $115 to $125.
  • Diagnostic bundles: Some clinics offer packages including blood panels and screenings.
  • Expert credentials: Academic professors often lead departments at JCI-accredited hospitals.
  • Follow-up terms: Many consultations include a free follow-up within 10 days.

Bookimed Expert Insight: Data shows a price trend linked to the hospital's international partnerships. Local chains like Memorial Health Group maintain fixed consultation rates across their network. Centers with US university affiliations may charge slightly more for specialized BHRT assessments. Booking through a network can stabilize your initial diagnostic costs.

Patient Consensus: Patients note the speed of getting specialist appointments. They appreciate that doctors explain blood results in great detail. Many mention feeling comfortable with the clear pricing provided before arrival.

Do hormone-therapy doctors in Turkey speak English?

Hormone therapy doctors in Turkey typically speak fluent English. Specialists at private networks like Memorial Hospital Group and Liv Hospital often train abroad. These experts frequently hold certifications from European or American medical boards. Bookimed manages all communication and provides translators for complex medical discussions.

  • International training: Many doctors completed fellowships in the United Kingdom or United States.
  • Board certifications: Leading specialists maintain memberships in global endocrine and oncology societies.
  • Dedicated coordinators: Private clinics provide English-speaking staff to manage your medical queries.
  • Digital consultations: Patients often speak with doctors via video before traveling to Turkey.

Bookimed Expert Insight: Data shows a strong link between academic background and language skills. Doctors at university hospitals, such as Koç University Hospital, often publish research in English. This academic focus means they are well-versed in international medical terminology.

Patient Consensus: Patients note that doctors explain hormone levels clearly in English. They felt comfortable asking questions during long consultations. Translators are always nearby if technical details get too complex.

Can Turkish hormone doctors coordinate care for international patients after I return home?

Turkish hormone doctors coordinate long-term care through dedicated international departments and remote monitoring systems. Accredited facilities maintain specialized teams to manage follow-up data. They work with your local practitioners to ensure treatment continuity. This process follows strict national medical tourism regulations.

  • International patient departments: Multilingual coordinators manage all remote communication and scheduling.
  • Telemedicine consultations: Doctors use virtual appointments to review symptoms and lab results.
  • Digital file sharing: Medical teams provide translated reports for your home-country physicians.
  • Lab coordination: Turkish endocrinologists specify exact markers for local blood tests.

Bookimed Expert Insight: Data shows that top Turkish specialists often hold memberships in the Endocrine Society. This ensures they follow global clinical guidelines. This alignment makes it easier for home-country doctors to accept the Turkish care plan. It also simplifies the transition for complex cases like fertility or thyroid management.

Patient Consensus: Patients note that using WhatsApp for quick doctor feedback is very helpful. They say the translated medical files make local pharmacy visits much smoother. Many felt reassured having a direct line to their Turkish team after flying back.

Which subspecialties do hormone-therapy doctors in Turkey focus on?

Hormone therapy doctors in Turkey focus on medical oncology, reproductive endocrinology, and metabolic diseases. These specialists manage hormone-sensitive cancers and fertility issues. They also treat thyroid disorders and pediatric growth delays. Doctors utilize molecular profiling to create personalized treatment plans.

  • Medical oncology: Specialists use androgen deprivation and aromatase inhibitors for cancer care.
  • Reproductive endocrinology: Doctors manage polycystic ovary syndrome (PCOS) and complex IVF stimulation protocols.
  • General endocrinology: Specialists treat diabetes, thyroid dysfunction, and adrenal gland disorders.
  • Pediatric endocrinology: Experts address juvenile diabetes and early or delayed puberty in children.

Bookimed Expert Insight: Data shows Turkish endocrinologists often hold dual expertise in metabolic disorders. Many specialists at Anadolu Medical Center and Medipol Mega have 20+ years of experience. This experience allows them to manage complex cases like pituitary tumors effectively.

Patient Consensus: Patients note the detailed care they receive for hormonal issues. Many say doctors explain the lab results very clearly. They feel comfortable with the professional and organized clinic environment.